Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19

Cardiovascular complications, including myocardial infarction, ischemic stroke, and pulmonary embolism, represent an important source of adverse outcomes in coronavirus disease-2019 (COVID-19). To assess the frequency of arterial and venous thromboembolic disease, risk factors, prevention and manage...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American College of Cardiology Vol. 76; no. 18; p. 2060
Main Authors:	Piazza, Gregory, Campia, Umberto, Hurwitz, Shelley, Snyder, Julia E, Rizzo, Samantha M, Pfeferman, Mariana B, Morrison, Ruth B, Leiva, Orly, Fanikos, John, Nauffal, Victor, Almarzooq, Zaid, Goldhaber, Samuel Z
Format:	Journal Article
Language:	English
Published:	United States 03.11.2020
Subjects:	Adult Aged Anticoagulants - therapeutic use Betacoronavirus Coronavirus Infections - complications Coronavirus Infections - mortality COVID-19 Female Humans Intensive Care Units - statistics & numerical data Male Massachusetts - epidemiology Middle Aged Pandemics Pneumonia, Viral - complications Pneumonia, Viral - mortality Registries Retrospective Studies Risk Factors SARS-CoV-2 Thromboembolism - epidemiology Thromboembolism - prevention & control Thromboembolism - virology Massachusetts COVID-19 cardiovascular disease thromboembolism anticoagulation myocardial infarction coronavirus deep venous thrombosis pulmonary embolism stroke
ISSN:	1558-3597, 1558-3597
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Cardiovascular complications, including myocardial infarction, ischemic stroke, and pulmonary embolism, represent an important source of adverse outcomes in coronavirus disease-2019 (COVID-19). To assess the frequency of arterial and venous thromboembolic disease, risk factors, prevention and management patterns, and outcomes in patients with COVID-19, the authors designed a multicenter, observational cohort study. We analyzed a retrospective cohort of 1,114 patients with COVID-19 diagnosed through our Mass General Brigham integrated health network. The total cohort was analyzed by site of care: intensive care (n = 170); hospitalized nonintensive care (n = 229); and outpatient (n = 715). The primary study outcome was a composite of adjudicated major arterial or venous thromboembolism. Patients with COVID-19 were 22.3% Hispanic/Latinx and 44.2% non-White. Cardiovascular risk factors of hypertension (35.8%), hyperlipidemia (28.6%), and diabetes (18.0%) were common. Prophylactic anticoagulation was prescribed in 89.4% of patients with COVID-19 in the intensive care cohort and 84.7% of those in the hospitalized nonintensive care setting. Frequencies of major arterial or venous thromboembolism, major cardiovascular adverse events, and symptomatic venous thromboembolism were highest in the intensive care cohort (35.3%, 45.9%, and 27.0 %, respectively) followed by the hospitalized nonintensive care cohort (2.6%, 6.1%, and 2.2%, respectively) and the outpatient cohort (0% for all). Major arterial or venous thromboembolism, major adverse cardiovascular events, and symptomatic venous thromboembolism occurred with high frequency in patients with COVID-19, especially in the intensive care setting, despite a high utilization rate of thromboprophylaxis.
AbstractList	Cardiovascular complications, including myocardial infarction, ischemic stroke, and pulmonary embolism, represent an important source of adverse outcomes in coronavirus disease-2019 (COVID-19).BACKGROUNDCardiovascular complications, including myocardial infarction, ischemic stroke, and pulmonary embolism, represent an important source of adverse outcomes in coronavirus disease-2019 (COVID-19).To assess the frequency of arterial and venous thromboembolic disease, risk factors, prevention and management patterns, and outcomes in patients with COVID-19, the authors designed a multicenter, observational cohort study.OBJECTIVESTo assess the frequency of arterial and venous thromboembolic disease, risk factors, prevention and management patterns, and outcomes in patients with COVID-19, the authors designed a multicenter, observational cohort study.We analyzed a retrospective cohort of 1,114 patients with COVID-19 diagnosed through our Mass General Brigham integrated health network. The total cohort was analyzed by site of care: intensive care (n = 170); hospitalized nonintensive care (n = 229); and outpatient (n = 715). The primary study outcome was a composite of adjudicated major arterial or venous thromboembolism.METHODSWe analyzed a retrospective cohort of 1,114 patients with COVID-19 diagnosed through our Mass General Brigham integrated health network. The total cohort was analyzed by site of care: intensive care (n = 170); hospitalized nonintensive care (n = 229); and outpatient (n = 715). The primary study outcome was a composite of adjudicated major arterial or venous thromboembolism.Patients with COVID-19 were 22.3% Hispanic/Latinx and 44.2% non-White. Cardiovascular risk factors of hypertension (35.8%), hyperlipidemia (28.6%), and diabetes (18.0%) were common. Prophylactic anticoagulation was prescribed in 89.4% of patients with COVID-19 in the intensive care cohort and 84.7% of those in the hospitalized nonintensive care setting. Frequencies of major arterial or venous thromboembolism, major cardiovascular adverse events, and symptomatic venous thromboembolism were highest in the intensive care cohort (35.3%, 45.9%, and 27.0 %, respectively) followed by the hospitalized nonintensive care cohort (2.6%, 6.1%, and 2.2%, respectively) and the outpatient cohort (0% for all).RESULTSPatients with COVID-19 were 22.3% Hispanic/Latinx and 44.2% non-White. Cardiovascular risk factors of hypertension (35.8%), hyperlipidemia (28.6%), and diabetes (18.0%) were common. Prophylactic anticoagulation was prescribed in 89.4% of patients with COVID-19 in the intensive care cohort and 84.7% of those in the hospitalized nonintensive care setting. Frequencies of major arterial or venous thromboembolism, major cardiovascular adverse events, and symptomatic venous thromboembolism were highest in the intensive care cohort (35.3%, 45.9%, and 27.0 %, respectively) followed by the hospitalized nonintensive care cohort (2.6%, 6.1%, and 2.2%, respectively) and the outpatient cohort (0% for all).Major arterial or venous thromboembolism, major adverse cardiovascular events, and symptomatic venous thromboembolism occurred with high frequency in patients with COVID-19, especially in the intensive care setting, despite a high utilization rate of thromboprophylaxis.CONCLUSIONSMajor arterial or venous thromboembolism, major adverse cardiovascular events, and symptomatic venous thromboembolism occurred with high frequency in patients with COVID-19, especially in the intensive care setting, despite a high utilization rate of thromboprophylaxis. Cardiovascular complications, including myocardial infarction, ischemic stroke, and pulmonary embolism, represent an important source of adverse outcomes in coronavirus disease-2019 (COVID-19). To assess the frequency of arterial and venous thromboembolic disease, risk factors, prevention and management patterns, and outcomes in patients with COVID-19, the authors designed a multicenter, observational cohort study. We analyzed a retrospective cohort of 1,114 patients with COVID-19 diagnosed through our Mass General Brigham integrated health network. The total cohort was analyzed by site of care: intensive care (n = 170); hospitalized nonintensive care (n = 229); and outpatient (n = 715). The primary study outcome was a composite of adjudicated major arterial or venous thromboembolism. Patients with COVID-19 were 22.3% Hispanic/Latinx and 44.2% non-White. Cardiovascular risk factors of hypertension (35.8%), hyperlipidemia (28.6%), and diabetes (18.0%) were common. Prophylactic anticoagulation was prescribed in 89.4% of patients with COVID-19 in the intensive care cohort and 84.7% of those in the hospitalized nonintensive care setting. Frequencies of major arterial or venous thromboembolism, major cardiovascular adverse events, and symptomatic venous thromboembolism were highest in the intensive care cohort (35.3%, 45.9%, and 27.0 %, respectively) followed by the hospitalized nonintensive care cohort (2.6%, 6.1%, and 2.2%, respectively) and the outpatient cohort (0% for all). Major arterial or venous thromboembolism, major adverse cardiovascular events, and symptomatic venous thromboembolism occurred with high frequency in patients with COVID-19, especially in the intensive care setting, despite a high utilization rate of thromboprophylaxis.
Author	Fanikos, John Goldhaber, Samuel Z Snyder, Julia E Nauffal, Victor Almarzooq, Zaid Leiva, Orly Rizzo, Samantha M Hurwitz, Shelley Campia, Umberto Pfeferman, Mariana B Piazza, Gregory Morrison, Ruth B
Author_xml	– sequence: 1 givenname: Gregory surname: Piazza fullname: Piazza, Gregory email: gpiazza@partners.org organization: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: gpiazza@partners.org – sequence: 2 givenname: Umberto surname: Campia fullname: Campia, Umberto organization: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 3 givenname: Shelley surname: Hurwitz fullname: Hurwitz, Shelley organization: Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 4 givenname: Julia E surname: Snyder fullname: Snyder, Julia E organization: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 5 givenname: Samantha M surname: Rizzo fullname: Rizzo, Samantha M organization: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 6 givenname: Mariana B surname: Pfeferman fullname: Pfeferman, Mariana B organization: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 7 givenname: Ruth B surname: Morrison fullname: Morrison, Ruth B organization: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 8 givenname: Orly surname: Leiva fullname: Leiva, Orly organization: Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 9 givenname: John surname: Fanikos fullname: Fanikos, John organization: Department of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 10 givenname: Victor surname: Nauffal fullname: Nauffal, Victor organization: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 11 givenname: Zaid surname: Almarzooq fullname: Almarzooq, Zaid organization: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts – sequence: 12 givenname: Samuel Z surname: Goldhaber fullname: Goldhaber, Samuel Z organization: Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33121712$$D View this record in MEDLINE/PubMed
BookMark	eNpNkElrwzAUhEVJaZb2D_RQdOzF7tPm5RjcLRBIKWl6NJItNwq2lFr2If--gqbQw_ANj-ExzBxNrLMaoVsCMQGSPBzig6yqmAKFGLIYUrhAMyJEFjGRp5N_form3h8AIMlIfoWmjBFKUkJnaPeuv4wf-hN2DV72g-6NbLG0Nd5p60aPt_vedcrpoNZUuHDdMVAOxlmPjcVvwWo7ePxphj0uNrvVY0Tya3TZyNbrmzMX6OP5aVu8RuvNy6pYrqOKUwZRLoVUlQTNs1RwllUsrxPCacYUKBmgQQBLWdNQqElaEyVYOErKleKSErpA979_j737HrUfys74SrettDq0LykXCSdcsCRE787RUXW6Lo-96WR_Kv-2oD9p1mHz
CitedBy_id	crossref_primary_10_1007_s11239_021_02475_7 crossref_primary_10_3390_jof9090897 crossref_primary_10_1097_CRD_0000000000000429 crossref_primary_10_1111_ene_14727 crossref_primary_10_1161_CIRCULATIONAHA_123_063901 crossref_primary_10_1186_s12879_025_10666_3 crossref_primary_10_1016_j_ahj_2021_02_001 crossref_primary_10_1007_s13679_021_00436_y crossref_primary_10_1055_a_2216_5848 crossref_primary_10_3390_biomedicines10102354 crossref_primary_10_1097_MD_0000000000027216 crossref_primary_10_1002_gch2_202100004 crossref_primary_10_1177_10760296211017668 crossref_primary_10_1007_s11239_021_02569_2 crossref_primary_10_1097_ACO_0000000000001076 crossref_primary_10_1016_j_vph_2021_106883 crossref_primary_10_1016_j_jcjo_2021_06_019 crossref_primary_10_1093_ehjqcco_qcac046 crossref_primary_10_1155_2022_7325060 crossref_primary_10_3390_v15051173 crossref_primary_10_1177_08850666211051960 crossref_primary_10_1016_j_medine_2024_502117 crossref_primary_10_1055_s_0041_1735200 crossref_primary_10_15420_ecr_2024_62 crossref_primary_10_1055_s_0043_1776713 crossref_primary_10_1080_17476348_2021_1899815 crossref_primary_10_1186_s12889_021_11051_w crossref_primary_10_1080_21548331_2021_2007648 crossref_primary_10_1111_imj_16145 crossref_primary_10_5582_bst_2023_01039 crossref_primary_10_1055_s_0044_1785487 crossref_primary_10_1016_j_jacc_2021_12_023 crossref_primary_10_1055_a_1817_8872 crossref_primary_10_1016_j_chest_2021_06_016 crossref_primary_10_1007_s00592_021_01751_5 crossref_primary_10_36290_vnl_2020_153 crossref_primary_10_3389_fpubh_2022_1022810 crossref_primary_10_3390_diseases10040118 crossref_primary_10_29254_2077_4214_2021_1_159_93_97 crossref_primary_10_1055_a_2096_9824 crossref_primary_10_36290_vnl_2021_075 crossref_primary_10_3389_fphar_2020_583914 crossref_primary_10_1371_journal_pone_0277544 crossref_primary_10_1038_s41598_025_04837_0 crossref_primary_10_1161_CIRCRESAHA_122_321541 crossref_primary_10_1007_s11547_021_01415_y crossref_primary_10_2217_fca_2020_0188 crossref_primary_10_1111_joim_13706 crossref_primary_10_1016_j_rpth_2023_100182 crossref_primary_10_1016_j_thromres_2024_02_021 crossref_primary_10_1016_j_jacc_2023_02_041 crossref_primary_10_1111_joim_13385 crossref_primary_10_1007_s11239_021_02394_7 crossref_primary_10_1016_j_jacc_2022_03_365 crossref_primary_10_1007_s11239_021_02429_z crossref_primary_10_1016_j_acvd_2021_10_004 crossref_primary_10_1177_15385744231174664 crossref_primary_10_1182_blood_2021012250 crossref_primary_10_1055_s_0041_1739235 crossref_primary_10_1007_s00508_021_01956_2 crossref_primary_10_1016_j_carpath_2021_107370 crossref_primary_10_3389_fimmu_2024_1428711 crossref_primary_10_1055_a_1962_4659 crossref_primary_10_1186_s40001_022_00655_6 crossref_primary_10_1007_s10072_021_05299_8 crossref_primary_10_1097_CCM_0000000000004967 crossref_primary_10_1155_2024_8838308 crossref_primary_10_1016_j_ejphar_2023_175501 crossref_primary_10_1016_j_radcr_2022_10_028 crossref_primary_10_2459_JCM_0000000000001284 crossref_primary_10_3390_biomedicines9080903 crossref_primary_10_1007_s12020_025_04401_w crossref_primary_10_1016_j_thromres_2021_06_014 crossref_primary_10_1016_j_thromres_2022_08_021 crossref_primary_10_1002_ajh_26384 crossref_primary_10_1186_s12933_021_01368_6 crossref_primary_10_2174_0113892037324425241018061548 crossref_primary_10_1161_CIRCRESAHA_122_319954 crossref_primary_10_1016_j_rpth_2023_102146 crossref_primary_10_3390_ijms241311132 crossref_primary_10_1016_j_tcm_2022_02_008 crossref_primary_10_1016_j_thromres_2023_05_019 crossref_primary_10_3390_microorganisms10091738 crossref_primary_10_1001_jamanetworkopen_2024_38541 crossref_primary_10_1089_sur_2022_193 crossref_primary_10_1055_a_1485_2372 crossref_primary_10_1016_j_hipert_2021_02_002 crossref_primary_10_1016_j_thromres_2021_12_010 crossref_primary_10_7717_peerj_16694 crossref_primary_10_3389_fped_2022_944743 crossref_primary_10_1161_STROKEAHA_121_034787 crossref_primary_10_1007_s11239_020_02364_5 crossref_primary_10_7554_eLife_86002 crossref_primary_10_1097_SLA_0000000000004700 crossref_primary_10_1016_j_medine_2025_502167 crossref_primary_10_1161_CIRCOUTCOMES_122_009652 crossref_primary_10_1016_j_thromres_2023_09_007 crossref_primary_10_1016_j_ophtha_2023_09_019 crossref_primary_10_3390_medicina58111554 crossref_primary_10_1007_s12262_022_03423_2 crossref_primary_10_3892_etm_2021_10471 crossref_primary_10_3390_v13040700 crossref_primary_10_1007_s00068_023_02265_1 crossref_primary_10_1001_jama_2020_23422 crossref_primary_10_1210_clinem_dgab792 crossref_primary_10_1053_j_semnuclmed_2021_06_017 crossref_primary_10_3390_cells10040933 crossref_primary_10_3390_biomedicines10030702 crossref_primary_10_1002_pul2_12113 crossref_primary_10_1002_rth2_12752 crossref_primary_10_1038_s42255_020_00339_7 crossref_primary_10_3390_jcm11092460 crossref_primary_10_1055_s_0041_1735628 crossref_primary_10_1177_10760296221120421 crossref_primary_10_1001_jamaophthalmol_2022_0632 crossref_primary_10_1007_s11239_021_02471_x crossref_primary_10_1007_s11239_022_02643_3 crossref_primary_10_1016_j_jbior_2021_100819 crossref_primary_10_1093_jscr_rjac532 crossref_primary_10_3389_fcvm_2021_700292 crossref_primary_10_1177_2050313X211022425 crossref_primary_10_1055_a_1755_8676 crossref_primary_10_3889_oamjms_2023_11203 crossref_primary_10_1080_21548331_2022_2029452 crossref_primary_10_1055_a_1983_3800 crossref_primary_10_14423_SMJ_0000000000001269 crossref_primary_10_1007_s11239_025_03078_2 crossref_primary_10_7759_cureus_31682 crossref_primary_10_1001_jama_2021_4152 crossref_primary_10_1016_j_jacc_2021_02_035 crossref_primary_10_1055_a_1661_0283 crossref_primary_10_1016_j_thromres_2022_06_007 crossref_primary_10_1080_20009666_2021_1922132 crossref_primary_10_1055_s_0042_1749661 crossref_primary_10_1590_1516_3180_2022_0171_r2_17102022 crossref_primary_10_1109_TASE_2024_3423391 crossref_primary_10_2147_JBM_S316014 crossref_primary_10_1161_JAHA_123_034186 crossref_primary_10_1016_j_jiac_2023_09_017 crossref_primary_10_1097_HCO_0000000000000958 crossref_primary_10_1016_j_tru_2021_100096 crossref_primary_10_1016_j_jacc_2020_09_543 crossref_primary_10_1371_journal_pone_0270195 crossref_primary_10_1016_j_jjcc_2021_12_007 crossref_primary_10_1016_j_amjms_2022_03_007 crossref_primary_10_2459_JCM_0000000000001556 crossref_primary_10_1177_15910199211035894 crossref_primary_10_1371_journal_pone_0302612 crossref_primary_10_1007_s11883_022_01032_8 crossref_primary_10_1177_10760296211051764 crossref_primary_10_1080_17476348_2021_1951707 crossref_primary_10_3390_v14061137 crossref_primary_10_1155_2021_4361844 crossref_primary_10_1007_s11886_022_01793_3 crossref_primary_10_1177_14703203251351110 crossref_primary_10_2147_CPAA_S429064 crossref_primary_10_1093_qjmed_hcab059 crossref_primary_10_1016_j_tcm_2020_12_004 crossref_primary_10_3390_life12071015 crossref_primary_10_1016_j_cpcardiol_2023_101669 crossref_primary_10_1038_s41598_023_44199_z crossref_primary_10_1177_10760296221074353 crossref_primary_10_1111_jth_15808 crossref_primary_10_1155_2021_4936571 crossref_primary_10_1161_CIRCULATIONAHA_122_061533 crossref_primary_10_3390_cells11020306 crossref_primary_10_1055_s_0042_1744302 crossref_primary_10_1007_s11684_023_1041_7 crossref_primary_10_12998_wjcc_v10_i27_9556 crossref_primary_10_1007_s11239_021_02413_7 crossref_primary_10_3390_jcm14165681 crossref_primary_10_1016_j_thromres_2021_09_021 crossref_primary_10_1186_s13054_021_03543_3 crossref_primary_10_7759_cureus_30603 crossref_primary_10_1146_annurev_med_042921_110257 crossref_primary_10_1097_MCP_0000000000000792 crossref_primary_10_3390_biom12010021 crossref_primary_10_1016_j_ahj_2021_08_016 crossref_primary_10_1161_CIRCRESAHA_122_321636 crossref_primary_10_3390_vaccines10020232 crossref_primary_10_3390_jpm11080709 crossref_primary_10_1111_bjh_17986 crossref_primary_10_1016_j_medin_2024_502117 crossref_primary_10_3389_fphar_2022_987816 crossref_primary_10_1016_j_jacasi_2022_09_005 crossref_primary_10_1007_s11606_025_09431_8 crossref_primary_10_1002_ehf2_14118 crossref_primary_10_1186_s12959_021_00346_y crossref_primary_10_12998_wjcc_v10_i3_762 crossref_primary_10_1016_j_thromres_2021_03_006 crossref_primary_10_3390_jcm11102926 crossref_primary_10_1007_s10238_022_00876_3 crossref_primary_10_1007_s40262_023_01244_4 crossref_primary_10_3389_fcimb_2022_1053039 crossref_primary_10_3389_fimmu_2024_1363410 crossref_primary_10_1111_joim_13338 crossref_primary_10_1016_j_biopha_2023_116055 crossref_primary_10_1177_10760296221141449 crossref_primary_10_1055_s_0041_1740152 crossref_primary_10_1016_j_jss_2021_11_014
ContentType	Journal Article
Copyright	Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Copyright_xml	– notice: Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.jacc.2020.08.070
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1558-3597
ExternalDocumentID	33121712
Genre	Journal Article Observational Study
GeographicLocations	Massachusetts
GeographicLocations_xml	– name: Massachusetts
GroupedDBID	--- --K --M .1- .FO .~1 0R~ 0SF 18M 1B1 1P~ 1~. 1~5 2WC 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ AABNK AABVL AACTN AAEDT AAEDW AAFTH AAIKJ AAKUH AALRI AAOAW AAQFI AAQQT AAXUO ABBQC ABFNM ABFRF ABLJU ABMAC ABMZM ABOCM ABVKL ACGFO ACGFS ACIUM ACJTP ACPRK ADBBV ADEZE ADVLN AEFWE AEKER AENEX AEVXI AEXQZ AFCTW AFETI AFRAH AFRHN AFTJW AGYEJ AHMBA AITUG AJOXV AJRQY AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ BAWUL BLXMC CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EO8 EO9 EP2 EP3 F5P FDB FEDTE FNPLU G-Q GBLVA GX1 HVGLF IHE IXB J1W K-O KQ8 L7B MO0 N9A NCXOZ NPM O-L O9- OA. OAUVE OK1 OL~ OZT P-8 P-9 P2P PC. PQQKQ Q38 ROL RPZ SCC SDF SDG SDP SES SSZ T5K TR2 UNMZH UV1 W8F WH7 WOQ WOW YYM YZZ Z5R 7X8 ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS EFLBG ~HD
ID	FETCH-LOGICAL-c4230-9a5abca0e4875438c39d614283b0ba283e050373ff20d17d1b5383ea24bb4a212
IEDL.DBID	7X8
ISSN	1558-3597
IngestDate	Sat Sep 27 23:22:06 EDT 2025 Wed Feb 19 02:30:19 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	18
Keywords	COVID-19 cardiovascular disease thromboembolism anticoagulation myocardial infarction coronavirus deep venous thrombosis pulmonary embolism stroke
Language	English
License	Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4230-9a5abca0e4875438c39d614283b0ba283e050373ff20d17d1b5383ea24bb4a212
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC7588178
PMID	33121712
PQID	2456414536
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2456414536 pubmed_primary_33121712
PublicationCentury	2000
PublicationDate	2020-11-03
PublicationDateYYYYMMDD	2020-11-03
PublicationDate_xml	– month: 11 year: 2020 text: 2020-11-03 day: 03
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of the American College of Cardiology
PublicationTitleAlternate	J Am Coll Cardiol
PublicationYear	2020
References	33121713 - J Am Coll Cardiol. 2020 Nov 3;76(18):2073-2075
References_xml	– reference: 33121713 - J Am Coll Cardiol. 2020 Nov 3;76(18):2073-2075
SSID	ssj0006819
Score	2.6806054
Snippet	Cardiovascular complications, including myocardial infarction, ischemic stroke, and pulmonary embolism, represent an important source of adverse outcomes in...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	2060
SubjectTerms	Adult Aged Anticoagulants - therapeutic use Betacoronavirus Coronavirus Infections - complications Coronavirus Infections - mortality COVID-19 Female Humans Intensive Care Units - statistics & numerical data Male Massachusetts - epidemiology Middle Aged Pandemics Pneumonia, Viral - complications Pneumonia, Viral - mortality Registries Retrospective Studies Risk Factors SARS-CoV-2 Thromboembolism - epidemiology Thromboembolism - prevention & control Thromboembolism - virology
Title	Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19
URI	https://www.ncbi.nlm.nih.gov/pubmed/33121712 https://www.proquest.com/docview/2456414536
Volume	76
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT4NAEN6oNcaL70d9ZU28btxlYYGTMVWjh9bG1Npbsy8sRqG2jb_f2YWmXkxMPAAHIIFhmMfOzPchdEFNaEWUBUREWroEJSKSZ5JoI4VWApTMSE82EXc6yWCQdusFt2ndVjm3id5Qm1K7NfJLV6ALWRhxcTX-JI41ylVXawqNZdTgEMo4rY4HC7RwkXhiD3CZCeEQOddDM1V_15vUDsIwoB7CM6a_h5je1dxt_vcht9BGHWTi60orttGSLXbQWrsuo--i_pN99SxvuMzcVV4LsSwM7nvIVtwbTcoPVVrY3nONWz_7znFe4G6FxjrFL_lshFuP_YcbwtI99Hx322vdk5pggWiIoihJZSSVltS6rCXkieapER6CTVEl4WAdWkzMsyyghsWGKTCP3MogVCqU4PT20UpRFvYQ4UAncIZFGRUKYoRIuoFfHRieKK2NZk10PpfYEBTYVSVkYeGNhguZNdFBJfbhuELaGHLOIGViwdEf7j5G6-5r-jlBfoIaGfy-9hSt6q9ZPp2cec2Afafb_gZ3lMF3
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Registry+of+Arterial+and+Venous+Thromboembolic+Complications+in+Patients+With+COVID-19&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.au=Piazza%2C+Gregory&rft.au=Campia%2C+Umberto&rft.au=Hurwitz%2C+Shelley&rft.au=Snyder%2C+Julia+E&rft.date=2020-11-03&rft.issn=1558-3597&rft.eissn=1558-3597&rft.volume=76&rft.issue=18&rft.spage=2060&rft_id=info:doi/10.1016%2Fj.jacc.2020.08.070&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1558-3597&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1558-3597&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1558-3597&client=summon